Filing Details

Accession Number:
0001123292-17-000694
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-16 17:37:06
Reporting Period:
2017-03-14
Filing Date:
2017-03-16
Accepted Time:
2017-03-16 17:37:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1588972 Recro Pharma Inc. REPH Pharmaceutical Preparations (2834) 261523233
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1602484 Scp Vitalife Partners (Israel) Ii, L.p. Suite 190
7 Great Valley Parkway
Malvern PA 19355
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-03-14 5,454 $8.04 760,662 No 4 S Direct
Common Stock Disposition 2017-03-15 6,399 $8.01 754,263 No 4 S Direct
Common Stock Disposition 2017-03-16 3,170 $7.93 751,093 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.73 to $8.26, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.84 to $8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.